141 related articles for article (PubMed ID: 8137996)
21. Normal blast colony formation: an in vitro tool for monitoring human bone marrow 'purging'.
Degliantoni G; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1986 Dec; 1(2):209-13. PubMed ID: 3332133
[TBL] [Abstract][Full Text] [Related]
22. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. I. Effects of in vitro culturing with IL-3 and GM-CSF on human and mouse bone marrow cells purged with mafosfamide (ASTA-Z).
Slavin S; Mumcuoglu M; Landesberg-Weisz A; Kedar E
Bone Marrow Transplant; 1989 Sep; 4(5):459-64. PubMed ID: 2676042
[TBL] [Abstract][Full Text] [Related]
23. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
24. Autologous transplant for chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Cottafavi L; Dotti GP; Rizzoli V
Bone Marrow Transplant; 1994 Sep; 14(3):425-32. PubMed ID: 7994267
[TBL] [Abstract][Full Text] [Related]
25. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
Mumcuoglu M; Naparstek E; Slavin S
Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907
[TBL] [Abstract][Full Text] [Related]
26. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC
Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
[TBL] [Abstract][Full Text] [Related]
27. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557).
Douay L; Mary JY; Giarratana MC; Najman A; Gorin NC
Exp Hematol; 1989 Jun; 17(5):429-32. PubMed ID: 2653856
[TBL] [Abstract][Full Text] [Related]
28. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
Yang H; Eaves C; de Lima M; Lee MS; Champlin RE; McMannis JD; Robinson SN; Niu T; Decker WK; Xing D; Ng J; Li S; Yao X; Eaves AC; Jones R; Andersson BS; Shpall EJ
Bone Marrow Transplant; 2006 Mar; 37(6):575-82. PubMed ID: 16435011
[TBL] [Abstract][Full Text] [Related]
29. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
Ratajczak MZ; Hijiya N; Catani L; DeRiel K; Luger SM; McGlave P; Gewirtz AM
Blood; 1992 Apr; 79(8):1956-61. PubMed ID: 1562723
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of doxorubicin in combination with mafosfamide for in vitro elimination of myeloid and lymphoid tumor cells from human bone marrow.
Domenech J; Georget MT; Gihana E; Colombat P; Brémond JL; Chassaigne M; Lamagnère JP; Binet C
Bone Marrow Transplant; 1992 Feb; 9(2):101-6. PubMed ID: 1571708
[TBL] [Abstract][Full Text] [Related]
31. The diverse effect of topoisomerase I specific inhibitor (camptothecin) on normal and BCR/ABL-dependent hematopoietic cells proliferation: therapeutic implications.
Fertała J; Nieborowska-Skórska M; Calabretta B; Skórski T
Folia Histochem Cytobiol; 1995; 33(3):187-92. PubMed ID: 8612872
[TBL] [Abstract][Full Text] [Related]
32. Use of cell-free retroviral vector preparations for transduction of cells from the marrow of chronic phase and blast crisis chronic myelogenous leukemia patients and from normal individuals.
Etkin M; Filaccio M; Ellerson D; Suh SP; Claxton D; Gaozza E; Brenner M; Moen R; Belmont J; Moore KA
Hum Gene Ther; 1992 Apr; 3(2):137-45. PubMed ID: 1391033
[TBL] [Abstract][Full Text] [Related]
33. Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution.
Gorin NC; Labopin M; Laporte JP; Douay L; Lopez M; Lesage S; Fouillard L; Isnard F; Jouet JP; Bellal N; Perot C; Van Den Akker J; Bauters F; Najman A
Exp Hematol; 1999 Dec; 27(12):1822-30. PubMed ID: 10641600
[TBL] [Abstract][Full Text] [Related]
34. Potent antileukemic activity of the novel agents norsegoline and dibezine.
Einat M; Nagler A; Lishner M; Amiel A; Yarkoni S; Rudi A; Gellerman G; Kashman Y; Fabian I
Clin Cancer Res; 1995 Aug; 1(8):823-9. PubMed ID: 9816051
[TBL] [Abstract][Full Text] [Related]
35. Molecular analysis of retroviral transduction in chronic myelogenous leukemia.
Claxton D; Suh SP; Filaccio M; Ellerson D; Gaozza E; Andersson B; Brenner M; Reading C; Feinberg A; Moen R
Hum Gene Ther; 1991; 2(4):317-21. PubMed ID: 1665348
[TBL] [Abstract][Full Text] [Related]
36. Abnormality of c-kit oncoprotein in certain patients with chronic myelogenous leukemia--potential clinical significance.
Inokuchi K; Yamaguchi H; Tarusawa M; Futaki M; Hanawa H; Tanosaki S; Dan K
Leukemia; 2002 Feb; 16(2):170-7. PubMed ID: 11840282
[TBL] [Abstract][Full Text] [Related]
37. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
Skorski T; Nieborowska-Skorska M; Barletta C; Malaguarnera L; Szcyzlik C; Chen ST; Lange B; Calabretta B
J Clin Invest; 1993 Jul; 92(1):194-202. PubMed ID: 8325984
[TBL] [Abstract][Full Text] [Related]
38. Autologous transplantation for chronic myelogenous leukemia with mafosfamide-treated marrow.
Rizzoli V; Mangoni L; Almici C; Caramatti C; Dotti GP; Carlo-Stella C
Stem Cells; 1993 Oct; 11 Suppl 3():25-30. PubMed ID: 8298474
[TBL] [Abstract][Full Text] [Related]
39. Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells.
Fauth F; Martin H; Sonnhoff S; Bialleck H; Wiesneth M; Mihanovic B; Hoelzer D
Bone Marrow Transplant; 2000 Apr; 25(8):831-6. PubMed ID: 10808203
[TBL] [Abstract][Full Text] [Related]
40. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
